Facebook Linkedin RSS Twitter Youtube
Home 2024

REGENXBIO

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III
Drug Discovery

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III

A New-Wave Biosensor Approach for Direct, Fast, and High-Throughput AAV Process Development
Bioprocessing

A New-Wave Biosensor Approach for Direct, Fast, and High-Throughput AAV Process Development

Gene Therapy Pioneers Share Genome Editing Insights at Chardan Conference
Drug Discovery

Gene Therapy Pioneers Share Genome Editing Insights at Chardan Conference

Viral Safety in AAV Production: How Affinity Chromatography Effectively Contributes
Multimedia

Viral Safety in AAV Production: How Affinity Chromatography Effectively Contributes

Dimension Therapeutics Spurns Regenxbio for Sweeter Ultragenyx Offer
Genome Editing

Dimension Therapeutics Spurns Regenxbio for Sweeter Ultragenyx Offer

Ultragenyx Offers $138M for Dimension Therapeutics, as Bidding War with Regenxbio Looms
Genome Editing

Ultragenyx Offers $138M for Dimension Therapeutics, as Bidding War with Regenxbio Looms

Regenxbio to Acquire Dimension Therapeutics
Genome Editing

Regenxbio to Acquire Dimension Therapeutics

Voyager Exercises Options for Regenx Gene Therapy Vectors
Genome Editing

Voyager Exercises Options for Regenx Gene Therapy Vectors

Biogen Licenses Regenxbio Vectors
Industry News

Biogen Licenses Regenxbio Vectors

Newly Capitalized REGENXBIO Targets Gene Therapy Market
Genome Editing

Newly Capitalized REGENXBIO Targets Gene Therapy Market

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.